Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CellSource Co., Ltd. ( (JP:4880) ) has provided an update.
CellSource Co., Ltd. reported its consolidated financial results for the fiscal year ended October 31, 2025, showing net sales of ¥3,711 million and a modest profit attributable to owners of the parent of ¥10 million. The company has prepared consolidated financial statements for the first time this fiscal year, making year-on-year comparisons unavailable. Despite a positive equity-to-asset ratio of 84.0%, the company forecasts a decrease in net sales and a loss for the next fiscal year, indicating potential challenges ahead.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen547.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry and is listed on the Tokyo Stock Exchange. The company is involved in the development and commercialization of cell-based therapies and regenerative medicine products, focusing on innovative solutions for healthcare.
Average Trading Volume: 75,523
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen9.55B
Learn more about 4880 stock on TipRanks’ Stock Analysis page.